ECONOMIC EVALUATION OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB plus DOCETAXEL FOR TREATMENT OF PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER AGAINST TREATMENT WITH TRASTUZUMAB plus DOCETAXEL plus PLACEBO, IN THE VENEZUELAN CONTEXT

被引：0
|
作者：
Romero, M. [1 ]
Huerfano, L. M. [2 ]
Acero, G. [1 ]
机构：
[1] Salutia Fdn, Bogota, Colombia
[2] Salutia Fdn, Res Ctr Econ Management & Hlth Technol, Bogota, Colombia
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN41
引用
收藏
页码：A822 / A822
页数：1
相关论文
共 50 条
  • [21] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Nigel Fleeman
    Adrian Bagust
    Sophie Beale
    Kerry Dwan
    Rumona Dickson
    Chris Proudlove
    Yenal Dundar
    PharmacoEconomics, 2015, 33 : 13 - 23
  • [22] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB plus DOCETAXEL VERSUS DOCETAXEL ALONE IN THE TREATMENT OF HER2+METASTATIC BREAST CANCER
    Athanasakis, K.
    Golna, C.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2011, 14 (07) : A449 - A449
  • [23] The efficacy of trastuzumab, pertuzumab, and docetaxel in patients with HER-2-positive metastatic breast cancer
    Liem, Jean A.
    Kurniawan, Andree
    Christiano, Joysya
    Argo, Teresa M.
    Law, Natasha K.
    Asafia, Darlene
    ANNALS OF ONCOLOGY, 2022, 33 : S538 - S538
  • [24] Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
    Veeraraghavan, Jamunarani
    Gutierrez, Carolina
    Sethunath, Vidyalakshmi
    Mehravaran, Sepideh
    Giuliano, Mario
    Shea, Martin J.
    Mitchell, Tamika
    Wang, Tao
    Nanda, Sarmistha
    Pereira, Resel
    Davis, Robert
    Goutsouliak, Kristina
    Qin, Lanfang
    De Angelis, Carmine
    Diala, Irmina
    Lalani, Alshad S.
    Nagi, Chandandeep
    Hilsenbeck, Susan G.
    Rimawi, Mothaffar F.
    Osborne, C. Kent
    Schiff, Rachel
    NPJ BREAST CANCER, 2021, 7 (01)
  • [25] Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
    Jamunarani Veeraraghavan
    Carolina Gutierrez
    Vidyalakshmi Sethunath
    Sepideh Mehravaran
    Mario Giuliano
    Martin J. Shea
    Tamika Mitchell
    Tao Wang
    Sarmistha Nanda
    Resel Pereira
    Robert Davis
    Kristina Goutsouliak
    Lanfang Qin
    Carmine De Angelis
    Irmina Diala
    Alshad S. Lalani
    Chandandeep Nagi
    Susan G. Hilsenbeck
    Mothaffar F. Rimawi
    C. Kent Osborne
    Rachel Schiff
    npj Breast Cancer, 7
  • [26] Randomized phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer
    Najagami, K.
    Inoue, K.
    Mizutani, M.
    Hozumi, Y.
    Fujiwara, Y.
    Masuda, N.
    Tsukamoto, F.
    Saito, M.
    Ohashi, Y.
    Sano, M.
    Noguchi, S.
    CANCER RESEARCH, 2009, 69 (02) : 241S - 242S
  • [27] Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer
    Crown, J.
    Kennedy, M. J.
    Tresca, P.
    Marty, M.
    Espie, M.
    Burris, H. A.
    DeSilvio, M.
    Lau, M. R.
    Kothari, D.
    Koch, K. M.
    Dieras, V.
    ANNALS OF ONCOLOGY, 2013, 24 (08) : 2005 - 2011
  • [28] Cost-Effectiveness Analysis of Pertuzumab Plus Trastuzumab and Docetaxel Compared With Trastuzumab and Docetaxel in the Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in Colombia
    Augusto Guevara-Cuellar, Cesar
    Parody-Rua, Elizabeth
    Paula Rengifo-Mosquera, Maria
    Del Mar Conde-Crespo, Maria
    Maicol Nunez-Castro, Jhon
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 32 : 109 - 118
  • [29] Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
    Dai, Wei Fang
    Beca, Jaclyn M.
    Nagamuthu, Chenthila
    Liu, Ning
    de Oliveira, Claire
    Earle, Craig C.
    Trudeau, Maureen
    Mercer, Rebecca E.
    Chan, Kelvin K. W.
    JAMA NETWORK OPEN, 2022, 5 (02)
  • [30] Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
    Swain, Sandra M.
    Ewer, Michael S.
    Cortes, Javier
    Amadori, Dino
    Miles, David
    Knott, Adam
    Clark, Emma
    Benyunes, Mark C.
    Ross, Graham
    Baselga, Jose
    ONCOLOGIST, 2013, 18 (03): : 257 - 264
12345